News

priMe update: visit of the South African clinical sites

We are pleased that after the long COVID lockdown we were able to visit the south African sites to touch base and to discuss the conduct of the trial and potential improvements. We thanks all centres for their warm welcome and their hospitality during our stay and hope that, once everything is more or less back to normal, we’ll meet more often in person again.

more

Updates on priMe

The priMe organizational team (VPM, SIIPL, DiagnoSearch, IAVI) met last week at SIIPL in Pune, India to discuss the status of the project and how to streamline certain procedures to achieve the milestones and bring the trial to success.

more

VPM1002 is a frontrunner tuberculosis (TB) vaccine candidate.

Did you know that the 100-year-old BCG is the only vaccine available to protect against TB, and the world urgently needs a better TB vaccine?

There are several vaccine candidates in the pipeline, and our VPM1002 is one of the most advanced ones. The Scientist reported about the latest updates in the TB vaccine development. Click here to read the full article.

more

Recruitment has started at all clinical centers

We are pleased to announce that all clinical trial centers, located in Kenya, Tanzania, Uganda, South Africa and Gabon, have started their recruitment and are actively enrolling participants into the pivotal phase III trial (priMe) of the novel tuberculosis vaccine VPM1002.

more

Update on priMe study

TB vaccine candidate being investigated to prevent TB infection in infants in Phase III priMe study. Read more!

more